Climb Bio (NASDAQ:CLYM) Sets New 52-Week High Following Analyst Upgrade

Climb Bio, Inc. (NASDAQ:CLYM)’s stock price hit a new 52-week high on Tuesday after HC Wainwright raised their price target on the stock from $15.00 to $20.00. HC Wainwright currently has a buy rating on the stock. Climb Bio traded as high as $12.48 and last traded at $11.12, with a volume of 1248701 shares. The stock had previously closed at $11.37.

Several other research firms have also weighed in on CLYM. BTIG Research increased their price objective on shares of Climb Bio from $8.00 to $19.00 and gave the stock a “buy” rating in a research note on Wednesday, May 6th. Robert W. Baird set a $21.00 target price on Climb Bio in a research note on Wednesday, May 6th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Climb Bio in a report on Monday, April 20th. Mizuho assumed coverage on Climb Bio in a research report on Wednesday, April 15th. They set an “outperform” rating and a $18.00 price target on the stock. Finally, Oppenheimer raised their price target on Climb Bio from $10.00 to $18.00 and gave the stock an “outperform” rating in a report on Tuesday, April 21st. Three analysts have rated the stock with a Strong Buy rating, nine have given a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Buy” and an average price target of $20.30.

More Climb Bio News

Here are the key news stories impacting Climb Bio this week:

• Positive Sentiment: Climb Bio announced it will present new budoprutug clinical data at the European Hematology Association (EHA) 2026 Congress in June, which could highlight progress in its lead program and support sentiment around the biotech pipeline. Climb Bio to Present New Budoprutug Clinical Data at European Hematology Association (EHA) 2026 Congress
• Positive Sentiment: HC Wainwright reiterated a Buy rating and raised its price target on Climb Bio to $20, signaling continued analyst confidence in the stock’s upside. Climb Bio (NASDAQ:CLYM) Given New $20.00 Price Target at HC Wainwright
• Positive Sentiment: HC Wainwright lifted earnings estimates for FY2026, FY2027 and several quarterly periods, suggesting a modestly improving outlook for losses as the company advances its clinical development.
• Neutral Sentiment: The company remains unprofitable, with analyst estimates still calling for losses through 2027, so the near-term story remains focused on pipeline execution rather than earnings power.

Hedge Funds Weigh In On Climb Bio

Large investors have recently bought and sold shares of the stock. Dimensional Fund Advisors LP bought a new stake in shares of Climb Bio during the 1st quarter worth about $715,000. Hsbc Holdings PLC boosted its holdings in shares of Climb Bio by 107.2% in the fourth quarter. Hsbc Holdings PLC now owns 24,744 shares of the company’s stock valued at $99,000 after acquiring an additional 12,800 shares in the last quarter. Seven Fleet Capital Management LP acquired a new position in shares of Climb Bio during the fourth quarter valued at approximately $306,000. Virtu Financial LLC acquired a new position in shares of Climb Bio during the fourth quarter valued at approximately $43,000. Finally, XTX Topco Ltd raised its holdings in Climb Bio by 19.4% during the fourth quarter. XTX Topco Ltd now owns 34,852 shares of the company’s stock worth $139,000 after purchasing an additional 5,668 shares in the last quarter. Institutional investors and hedge funds own 69.76% of the company’s stock.

Climb Bio Price Performance

The stock has a market cap of $653.34 million, a P/E ratio of -14.63 and a beta of 0.02. The company has a fifty day moving average of $8.23 and a 200 day moving average of $5.33.

Climb Bio (NASDAQ:CLYM) last issued its quarterly earnings results on Thursday, May 7th. The company reported ($0.20) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.26) by $0.06. As a group, analysts anticipate that Climb Bio, Inc. will post -0.92 EPS for the current year.

About Climb Bio

Climb Bio Therapeutics, Inc is a clinical-stage biotechnology company focused on the discovery and development of engineered protein therapeutics for the treatment of cancer and immune-mediated disorders. The company’s mission centers on designing biologics with enhanced specificity and functional activity to engage key cellular targets and improve patient outcomes in areas of high unmet need.

At the heart of Climb Bio’s approach is its proprietary protein engineering platform, which combines mammalian cell display, directed evolution and computational modeling.